MedTrace Logo

Careseng 1370 for Healthy Volunteers

NCT03974516 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-11-22

Study results available
· View outcomes & findings →

Summary

This study will be performed in healthy volunteers in a conventional 3+3 dose-escalation design.

Conditions

  • Chemotherapy-induced Myelosuppression

Interventions

DRUG

Careseng 1370

Careseng 1370 should be taken around 1 hour before meal.

Sponsors & Collaborators

  • i Cure Biotech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-10
Primary Completion
2022-03-11
Completion
2022-03-11

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03974516 on ClinicalTrials.gov